Chris Schelling

Mr. Schelling has 20 years of commercial strategy and orphan drug development expertise and has served as a director and as President and Chief Executive Officer since September 2017. Mr. Schelling founded Acer in December 2013 and served as a director from that time until 2017. From December 2013 to February 2016, he served as Acer’s Chief Operating Officer, and from February 2016 until 2017, he served as Acer’s President and Chief Executive Officer. Prior to founding Acer, he served as Executive Director of Strategic Marketing at BioMarin Pharmaceutical Inc., a Nasdaq-listed biotechnology company, from May 2006 to October 2012. Mr. Schelling also founded Censa Pharmaceuticals Inc. in 2015 and currently serves as a director. He has also served as a director at Cascade Prodrug, Inc. since June 2017. He has also held roles at Abgenix, Inc., Cell Therapeutics, Inc., Stanford Research Institute Consulting and Organon. Mr. Schelling earned a B.A. in biology and history from Carroll College